Description
Description | Cot inhibitor-2 is a cot (Tpl2/MAP3K8) inhibitor (IC50: 1.6 nM) with potency, selectivity and oral activity. cot inhibitor-2 inhibits LPS-stimulated TNF-α production in human whole blood with an IC50 of 0.3 μM. |
Targets&IC50 | TNF-α production (human whole blood):0.3 μM, Cot (Tpl2/MAP3K8):1.6 nM |
In vivo |
Cot inhibitor-2 (100 mg/kg ; orally ; rats) showed a Cmax of 517 ng/mL (0.89 μM) and AUC of 4841 ng•h/mL.[1] Cot inhibitor-2 (25 mg/kg ; p.o. ; rats) is tested in the LPS-induced TNF-α production model in female Sprague-Dawley rats that Cot inhibitor-2 inhibits LPS-induced TNF-α production by 83%.[1] |
Molecular Weight |
539.43 |
Formula | C26H25Cl2FN8 |
CAS No. | 915363-56-3 |
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 36.0 mg/mL (66.7 mM),
Sonication is recommended.